Evidence map›Paper›PMID 39090499›Full record

ArticleAnnals of surgical oncology2024

Clinical Effectiveness and Safety of Transarterial Chemoembolization: Hepatic Artery Infusion Chemotherapy Plus Tyrosine Kinase Inhibitors With or Without Programmed Cell Death Protein-1 Inhibitors for Unresectable Hepatocellular Carcinoma-A Retrospective Study.

Yue Chen, Luyao Jia, Yu Li, Wenhao Cui, Jukun Wang, Chao Zhang, Chunjing Bian, Zhenshun Wang, Dongdong Lin, Tao Luo

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yue ChenDepartment of General Surgery, Xuanwu Hospital, Capital Medical University, Beijing, China.
Luyao JiaDepartment of General Surgery, Xuanwu Hospital, Capital Medical University, Beijing, China.
Yu LiDepartment of General Surgery, Xuanwu Hospital, Capital Medical University, Beijing, China.
Wenhao CuiEmergency Medicine Department, Xuanwu Hospital, Capital Medical University, Beijing, China.
Jukun WangDepartment of General Surgery, Xuanwu Hospital, Capital Medical University, Beijing, China.
Chao ZhangDepartment of General Surgery, Xuanwu Hospital, Capital Medical University, Beijing, China.
Chunjing BianDepartment of General Surgery, Xuanwu Hospital, Capital Medical University, Beijing, China.
Zhenshun WangDepartment of General Surgery, Xuanwu Hospital, Capital Medical University, Beijing, China.
Dongdong LinDepartment of General Surgery, Xuanwu Hospital, Capital Medical University, Beijing, China.
Tao LuoDepartment of General Surgery, Xuanwu Hospital, Capital Medical University, Beijing, China. Taoluo35@126.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLocoregional treatment with transarterial chemoembolization (TACE) or hepatic artery infusion chemotherapy (HAIC) and systemic targeted immunotherapy with tyrosine kinase inhibitors (TKI) and programmed cell death protein-1 (PD-1) inhibitors in the treatment of unresectable hepatocellular carcinoma (uHCC) have achieved promising efficacy. The retrospective study aimed to evaluate the efficacy and safety of TACE and HAIC plus TKI with or without PD-1 for uHCC. PATIENTS AND

methodsFrom November 2020 to February 2024, the data of 44 patients who received TACE-HAIC + TKI + PD-1 (THKP group) and 34 patients who received TACE-HAIC + TKI (THK group) were retrospectively analyzed. Primary outcomes were overall survival (OS) and progress-free survival (PFS), and secondary outcomes were objective response rate (ORR), disease control rate (DCR), conversion rates, and adverse events (AEs).

resultsA total of 78 patients were recruited in our single-center study. The patients in THKP group had prolonged median OS [25 months, 95% confidence interval (CI) 24.0-26.0 vs 18 months, 95% CI 16.1-19.9; p = 0.000278], median PFS [16 months, 95% CI 14.1-17.9 vs 12 months 95% CI 9.6-14.4; p = 0.004] and higher ORR (38.6% vs 23.5%, p = 0. 156) and DCR (88.6% vs 64.7%, p = 0.011) compared with those in THK group. Multivariate analysis showed that treatment option and alpha-fetoprotein (AFP) level were independent prognostic factors of OS and PFS. The frequency of AEs were similar between the two groups.

conclusionsThe THKP group had better efficacy for uHCC than the THK group, with acceptable safety.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, HepatocellularChemoembolization, TherapeuticHepatic ArteryInfusions, Intra-ArterialLiver NeoplasmsProtein Kinase InhibitorsAdultAgedCombined Modality TherapyFemaleFollow-Up StudiesHumansImmune Checkpoint InhibitorsMaleMiddle AgedImmune Checkpoint InhibitorsPDCD1 protein, humanProgrammed Cell Death 1 ReceptorProtein Kinase InhibitorsTyrosine Kinase InhibitorsHepatic arterial infusion chemotherapyProgrammed cell death protein-1 inhibitorsTransarterial chemotherapy embolizationTyrosine kinase inhibitorUnresectable hepatocellular carcinoma

Identifiers

PMID39090499

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.